Alector licenses AL050 GCase program to Genentech for $100M upfront and up to $1.17B milestones

Alector, Inc.

Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy.
Alector receives $100 million upfront and is eligible for up to $1.17 billion in development, regulatory, and commercial milestones plus tiered royalties.
Alector exercised its Spur option and will pay Spur $15 million plus a teens percentage of Genentech milestone and other non-royalty partnering income.
Preliminary cash and marketable securities were about $138.7 million as of Sept 30, 2026, or $223.7 million pro forma after Genentech upfront and Spur payment.
The Genentech deal extends Alector's cash runway into 2029; Alector will host an R&D webinar on Oct 13, 2026 for AL137, AL164, and AL062.

item 1.01 item 2.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.